JP2010519543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519543A5 JP2010519543A5 JP2009550924A JP2009550924A JP2010519543A5 JP 2010519543 A5 JP2010519543 A5 JP 2010519543A5 JP 2009550924 A JP2009550924 A JP 2009550924A JP 2009550924 A JP2009550924 A JP 2009550924A JP 2010519543 A5 JP2010519543 A5 JP 2010519543A5
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- acid content
- total fatty
- relative
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 579
- 229930195729 fatty acid Natural products 0.000 claims description 579
- 239000000194 fatty acid Substances 0.000 claims description 579
- 150000004665 fatty acids Chemical class 0.000 claims description 576
- 239000002207 metabolite Substances 0.000 claims description 352
- 150000002632 lipids Chemical class 0.000 claims description 301
- 239000003550 marker Substances 0.000 claims description 299
- 206010012601 diabetes mellitus Diseases 0.000 claims description 255
- 238000000034 method Methods 0.000 claims description 149
- 210000002381 plasma Anatomy 0.000 claims description 122
- 101100321670 Fagopyrum esculentum FA18 gene Proteins 0.000 claims description 106
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 99
- 239000008103 glucose Substances 0.000 claims description 98
- 101100029138 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PE16 gene Proteins 0.000 claims description 76
- 238000011282 treatment Methods 0.000 claims description 70
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 67
- 239000003814 drug Substances 0.000 claims description 59
- 206010022489 Insulin Resistance Diseases 0.000 claims description 58
- 229940079593 drug Drugs 0.000 claims description 57
- 210000004369 blood Anatomy 0.000 claims description 56
- 239000008280 blood Substances 0.000 claims description 56
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 51
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 51
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 49
- 210000002966 serum Anatomy 0.000 claims description 48
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 37
- 239000000090 biomarker Substances 0.000 claims description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 30
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 26
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 24
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims description 23
- 108010016731 PPAR gamma Proteins 0.000 claims description 21
- 230000007423 decrease Effects 0.000 claims description 21
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims description 20
- 210000001124 body fluid Anatomy 0.000 claims description 20
- 239000010839 body fluid Substances 0.000 claims description 20
- 230000002596 correlated effect Effects 0.000 claims description 20
- 229960004203 carnitine Drugs 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 19
- 108090001030 Lipoproteins Proteins 0.000 claims description 18
- 102000004895 Lipoproteins Human genes 0.000 claims description 18
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 17
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 15
- 238000005259 measurement Methods 0.000 claims description 15
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 15
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 14
- 101100069385 Toxoplasma gondii GRA6 gene Proteins 0.000 claims description 14
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 238000003018 immunoassay Methods 0.000 claims description 12
- 238000004949 mass spectrometry Methods 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- JHPNVNIEXXLNTR-UHFFFAOYSA-O 4-(trimethylammonio)butanoic acid Chemical compound C[N+](C)(C)CCCC(O)=O JHPNVNIEXXLNTR-UHFFFAOYSA-O 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 10
- 238000004587 chromatography analysis Methods 0.000 claims description 10
- 208000004104 gestational diabetes Diseases 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 208000007683 Pediatric Obesity Diseases 0.000 claims description 8
- 101001067830 Mus musculus Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 claims description 7
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 4
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims description 4
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000007824 enzymatic assay Methods 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 115
- 150000001840 cholesterol esters Chemical class 0.000 description 109
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 84
- 239000000203 mixture Substances 0.000 description 40
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 27
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 21
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 21
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 21
- 235000021588 free fatty acids Nutrition 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 150000003626 triacylglycerols Chemical class 0.000 description 18
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical class CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 17
- -1 Eicosanoids Eicosanoids Chemical class 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 208000001280 Prediabetic State Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 150000002066 eicosanoids Chemical class 0.000 description 10
- 238000007410 oral glucose tolerance test Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 230000037356 lipid metabolism Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 210000004880 lymph fluid Anatomy 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000035150 Hypercholesterolemia Diseases 0.000 description 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000001952 enzyme assay Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 6
- 201000008980 hyperinsulinism Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 150000008105 phosphatidylcholines Chemical class 0.000 description 6
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 6
- 230000007863 steatosis Effects 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- ZGNBLKBZJBJFDG-ZETCQYMHSA-N O-malonyl-D-carnitine Chemical compound C[N+](C)(C)C[C@H](CC(O)=O)OC(=O)CC([O-])=O ZGNBLKBZJBJFDG-ZETCQYMHSA-N 0.000 description 5
- 108010015181 PPAR delta Proteins 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 239000003613 bile acid Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 150000003432 sterols Chemical class 0.000 description 5
- 235000003702 sterols Nutrition 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 102000000536 PPAR gamma Human genes 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VVPRQWTYSNDTEA-LLVKDONJSA-N O-hexanoyl-L-carnitine Chemical compound CCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VVPRQWTYSNDTEA-LLVKDONJSA-N 0.000 description 3
- 102000023984 PPAR alpha Human genes 0.000 description 3
- 206010036049 Polycystic ovaries Diseases 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 230000000678 effect on lipid Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- 102000014777 Adipokines Human genes 0.000 description 2
- 108010078606 Adipokines Proteins 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-O O-acetylcarnitinium Chemical compound CC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-O 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960001009 acetylcarnitine Drugs 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000478 adipokine Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 208000015124 ovarian disease Diseases 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical class CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102100026515 Cytochrome P450 2S1 Human genes 0.000 description 1
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Chemical class OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101000806846 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 1
- 101000835083 Homo sapiens Tissue factor pathway inhibitor 2 Proteins 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
- UFPQIRYSPUYQHK-VRKJBCFNSA-N Leukotriene A4 Natural products CCCCCC=C/CC=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(=O)O UFPQIRYSPUYQHK-VRKJBCFNSA-N 0.000 description 1
- 102100023758 Leukotriene C4 synthase Human genes 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- PSHXNVGSVNEJBD-LJQANCHMSA-N O-tetradecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C PSHXNVGSVNEJBD-LJQANCHMSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100033075 Prostacyclin synthase Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010069102 Thromboxane-A synthase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000002171 adipose macrophage Anatomy 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- NGXUUAFYUCOICP-UHFFFAOYSA-N aminometradine Chemical group CCN1C(=O)C=C(N)N(CC=C)C1=O NGXUUAFYUCOICP-UHFFFAOYSA-N 0.000 description 1
- 229960001887 aminometradine Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000841 delta opiate receptor agonist Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940077085 diagnostic agent for diabetes testing Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000002770 isoprostane group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- 108010087711 leukotriene-C4 synthase Proteins 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- LTYOQGRJFJAKNA-VFLPNFFSSA-N malonyl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-VFLPNFFSSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010064377 prostacyclin synthetase Proteins 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90297607P | 2007-02-22 | 2007-02-22 | |
| US93176607P | 2007-05-24 | 2007-05-24 | |
| US2185308P | 2008-01-17 | 2008-01-17 | |
| PCT/US2008/002357 WO2008106054A2 (en) | 2007-02-22 | 2008-02-22 | Metabolic markers of diabetic conditions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010519543A JP2010519543A (ja) | 2010-06-03 |
| JP2010519543A5 true JP2010519543A5 (enExample) | 2011-04-07 |
Family
ID=39721790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550924A Pending JP2010519543A (ja) | 2007-02-22 | 2008-02-22 | 糖尿病状態の代謝マーカーおよびその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100197028A1 (enExample) |
| EP (1) | EP2126589A4 (enExample) |
| JP (1) | JP2010519543A (enExample) |
| CN (1) | CN101802620A (enExample) |
| AU (1) | AU2008219700B2 (enExample) |
| BR (1) | BRPI0807612A2 (enExample) |
| CA (1) | CA2678670A1 (enExample) |
| WO (1) | WO2008106054A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2407562A1 (en) * | 2006-05-08 | 2012-01-18 | Tethys Bioscience, Inc. | Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets |
| JP2011528117A (ja) * | 2008-07-15 | 2011-11-10 | メタノミクス ヘルス ゲーエムベーハー | 胃バイパス及びそれに関連する状態を診断する手段及び方法 |
| WO2010114897A1 (en) * | 2009-03-31 | 2010-10-07 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
| US11835503B2 (en) * | 2009-05-28 | 2023-12-05 | The Cleveland Clinic Foundation | TMA-formation inhibitor treatment for elevated TMA-containing compound diseases |
| CA2790371C (en) * | 2009-05-28 | 2020-09-01 | The Cleveland Clinic Foundation | Trimethylamine-containing compounds for diagnosis and prediction of disease |
| JP2013509588A (ja) * | 2009-10-29 | 2013-03-14 | テシス バイオサイエンス， インコーポレイテッド | ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー |
| EP3273247A1 (en) | 2010-06-10 | 2018-01-24 | Metanomics Health GmbH | Methods for the diagnosis of liver diseases |
| US10226209B2 (en) | 2010-10-15 | 2019-03-12 | Brain Sentinel, Inc. | Method and apparatus for classification of seizure type and severity using electromyography |
| KR101303825B1 (ko) * | 2011-06-02 | 2013-09-05 | 연세대학교 산학협력단 | 혈장 대사체를 이용한 제2형 당뇨병 진단 키트 |
| CA2840101A1 (en) * | 2011-07-05 | 2013-01-10 | Lgch, Inc. | Method and apparatus for detecting seizures |
| JP6158186B2 (ja) * | 2011-09-14 | 2017-07-05 | メタボロン，インコーポレイテッド | インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法 |
| CN102495217B (zh) * | 2011-12-06 | 2014-06-25 | 黄传峰 | 一种临床病例监测管理系统 |
| CN105008931A (zh) * | 2013-03-08 | 2015-10-28 | 佐拉生物科学公司 | 非高密度脂蛋白来源的cvd标志物 |
| AU2014377039A1 (en) | 2014-01-08 | 2016-05-26 | Société des Produits Nestlé S.A. | Biomarkers for epicardial adipose tissue |
| WO2015109116A1 (en) * | 2014-01-15 | 2015-07-23 | The Regents Of The University Of California | Metabolic screening for gestational diabetes |
| CN107076753B (zh) * | 2014-09-30 | 2019-01-18 | 深圳华大基因科技有限公司 | 肥胖人群特异性生物标志组合物及其用途 |
| US11255866B2 (en) * | 2015-02-26 | 2022-02-22 | Wisconsin Alumni Research Foundation | Methods for predicting glucoregulatory dysfunction via diacylglycerol fatty acid species concentrations |
| CN105424841B (zh) * | 2015-12-25 | 2017-11-03 | 齐炼文 | 用于诊断冠状动脉粥样硬化的代谢标志物 |
| CN105486773A (zh) * | 2015-12-25 | 2016-04-13 | 齐炼文 | 用于诊断冠心病的代谢标志物 |
| CN105628809B (zh) * | 2015-12-25 | 2018-04-03 | 中国药科大学 | 用于诊断区分冠状动脉粥样硬化和冠心病的代谢标志物 |
| CN106979982B (zh) * | 2016-01-19 | 2021-01-05 | 上海市第六人民医院 | 一种用于糖尿病风险预测、治疗评价的方法及试剂盒 |
| CN105486778B (zh) * | 2016-01-25 | 2017-11-03 | 齐炼文 | 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物 |
| CN105445408B (zh) * | 2016-01-25 | 2018-06-12 | 齐炼文 | 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物 |
| CN107121540B (zh) * | 2016-02-24 | 2020-06-12 | 中国科学院上海营养与健康研究所 | 酰基肉碱谱或其检测试剂在2型糖尿病发病风险预测中的应用 |
| CN106483212B (zh) * | 2016-09-22 | 2019-03-01 | 南京医科大学 | 与特发性男性不育相关的尿液雌激素代谢物标志物及其检测方法和应用 |
| CN106680473B (zh) * | 2017-01-23 | 2019-04-09 | 首都医科大学附属北京朝阳医院 | 生物标志物在筛选治疗或缓解代谢综合征的药物中的用途 |
| CN108152502A (zh) * | 2017-11-23 | 2018-06-12 | 上海阿趣生物科技有限公司 | 可用于检测糖尿病早期的组合标志物及其用途 |
| KR102377089B1 (ko) | 2018-11-27 | 2022-03-21 | 대한민국 | 전당뇨 진단 키트 및 진단 방법 |
| CN109709228B (zh) * | 2019-01-14 | 2022-06-14 | 上海市内分泌代谢病研究所 | 脂质联合标志物在制备诊断糖尿病的检测试剂或检测物的用途 |
| CN112697889B (zh) * | 2019-10-22 | 2022-03-08 | 中国科学院大连化学物理研究所 | 一种血清代谢标志物的用途及检测试剂盒 |
| JP6725928B1 (ja) * | 2020-02-13 | 2020-07-22 | 東洋インキＳｃホールディングス株式会社 | 回帰モデル作成方法、回帰モデル作成装置、及び、回帰モデル作成プログラム |
| CN112268962B (zh) * | 2020-09-08 | 2022-12-23 | 南京医科大学 | 长链酰基肉碱作为缺血性脑卒中生物标志物的应用 |
| CN112180013B (zh) * | 2020-09-29 | 2022-11-15 | 上海脉示生物技术有限公司 | 用于心肌梗死诊断的肠道微生物代谢标志物组合物及其检测方法和应用 |
| JP7517036B2 (ja) * | 2020-09-30 | 2024-07-17 | 東ソー株式会社 | 統計的手法によるクロマトグラムの分類方法 |
| CN112230003B (zh) * | 2020-11-05 | 2022-06-21 | 江苏省中医院 | 三种血清脂质联合用于糖尿病肾病诊断的用途 |
| CN112630330B (zh) * | 2020-12-08 | 2021-12-21 | 河北医科大学第二医院 | 小分子物质在脑梗死诊断中的应用 |
| WO2022133738A1 (zh) * | 2020-12-22 | 2022-06-30 | 中山大学附属第一医院 | 一种术前鉴别甲状腺良恶性结节的生物标志物、试剂盒及其应用 |
| CN112986425B (zh) * | 2021-02-09 | 2023-07-04 | 首都医科大学 | Pm2.5对脂质代谢影响的检测标志物及应用 |
| CN113008972B (zh) * | 2021-02-26 | 2023-03-24 | 南芯芯仪(广州)制造有限公司 | 用于妊娠期糖尿病诊断的血清代谢标志物及其应用 |
| CN115112776B (zh) * | 2021-03-18 | 2023-07-04 | 中国科学院大连化学物理研究所 | 联合标志物及在诊断心房颤动中应用及诊断试剂或试剂盒 |
| CN113484511B (zh) * | 2021-06-30 | 2023-07-04 | 华中科技大学 | 妊娠期糖尿病的孕早期血液脂质生物标志物的筛选及应用 |
| CN114317671B (zh) * | 2021-12-27 | 2024-04-16 | 复旦大学附属儿科医院 | 可作为1型糖尿病生物标志物的肠道细菌和粪便代谢物及其应用 |
| CN117169365A (zh) * | 2023-08-18 | 2023-12-05 | 上海市内分泌代谢病研究所 | 多不饱和脂肪酸联合标志物在制备诊断糖尿病的检测产品中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002230848B2 (en) * | 2000-12-14 | 2008-01-24 | The Brigham And Women's Hospital, Inc. | Inflammatory markers for detection and prevention of diabetes mellitus |
| CA2459508A1 (en) * | 2001-09-24 | 2003-04-03 | Lipomics Technologies, Inc. | Methods of using quantitative lipid metabolome data |
| US20060088860A1 (en) * | 2004-09-13 | 2006-04-27 | Lipomics Technologies, Inc. | Metabolite markers for weight management |
| US20070218519A1 (en) * | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
-
2008
- 2008-02-22 EP EP20080725946 patent/EP2126589A4/en not_active Ceased
- 2008-02-22 CA CA002678670A patent/CA2678670A1/en not_active Abandoned
- 2008-02-22 AU AU2008219700A patent/AU2008219700B2/en not_active Ceased
- 2008-02-22 US US12/528,065 patent/US20100197028A1/en not_active Abandoned
- 2008-02-22 WO PCT/US2008/002357 patent/WO2008106054A2/en not_active Ceased
- 2008-02-22 BR BRPI0807612-0A patent/BRPI0807612A2/pt not_active Application Discontinuation
- 2008-02-22 JP JP2009550924A patent/JP2010519543A/ja active Pending
- 2008-02-22 CN CN200880012978A patent/CN101802620A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519543A5 (enExample) | ||
| JP2010519543A (ja) | 糖尿病状態の代謝マーカーおよびその使用法 | |
| EP2607902B1 (en) | Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof | |
| Hameed et al. | Altered metabolome of lipids and amino acids species: a source of early signature biomarkers of T2DM | |
| JP6158186B2 (ja) | インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法 | |
| WO2013139584A1 (en) | Hydroxy-sphingomyelin 22:1 as biomarker for healthy ageing | |
| WO2013139580A1 (en) | Phenylacetylglutamine as biomarker for healthy ageing | |
| Zhang et al. | Human serum poly-and perfluoroalkyl substance concentrations and their associations with gestational diabetes mellitus | |
| Zhao et al. | Chemometrics strategy coupled with high resolution mass spectrometry for analyzing and interpreting comprehensive metabolomic characterization of hyperlipemia | |
| WO2013139579A1 (en) | 9-oxo-octadecadienoic acid (9-oxo-hode) as as biomarker for healthy ageing | |
| WO2013139583A1 (en) | P-cresol sulphate as biomarker for healthy ageing | |
| Djekic et al. | Metabolomics in atherosclerosis | |
| KR101598597B1 (ko) | 혈장 대사체를 이용한 고-ldl-콜레스테롤 질환 진단 장치 및 방법 | |
| Mousa et al. | Novel lipidomic signature associated with metabolic risk in women with and without polycystic ovary syndrome | |
| WO2013139582A1 (en) | 1-o-alkyl-2-acylglycerophosphocholine (pc-o) 40:1 as biomarker for healthy ageing | |
| US20220308071A1 (en) | Methods and compositions for determination of liver fibrosis | |
| Jain et al. | Identification of novel plasma lipid markers of cardiovascular disease risk in White and Black women | |
| Meuronen | Gene x diet interactions and fatty acid metabolism: FADS genotype and dietary polyunsaturated fatty acids | |
| Jain et al. | Author contributions | |
| 李泳翰 | Development and application of highly sensitive LC/MS analysis of oxylipins and short-chain fatty acids | |
| Pickens et al. | Prostaglandins, Leukotrienes and Essential Fatty Acids | |
| Djekic et al. | IJC Metabolic & Endocrine | |
| HK1131209B (en) | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |